2015
DOI: 10.1055/s-0035-1557112
|View full text |Cite
|
Sign up to set email alerts
|

AKI and Genetics: Evolving Concepts in the Genetics of Acute Kidney Injury: Implications for Pediatric AKI

Abstract: In spite of recent advances in the field of acute kidney injury (AKI) research, morbidity and mortality remain high for AKI sufferers. The study of genetic influences in AKI pathways is an evolving field with potential for improving outcomes through the identification of risk and protective factors at the individual level that may in turn allow for the development of rational therapeutic interventions. Studies of single nucleotide polymorphisms, individual susceptibility to nephrotoxic medications, and epigene… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 79 publications
(79 reference statements)
0
1
0
Order By: Relevance
“…16,17 It is becoming increasingly apparent that genetic heterogeneity within patient cohorts adds another element of complexity that may affect the response to promising therapies, and research initiatives in this area on relevant patient populations will hopefully inform the design of better preclinical models. 18-21 In contrast, preclinical studies are typically performed on pure disease processes with minimal consideration given to the genetic background of the model or cell line chosen. 22 The context of treatment must also be considered—many preclinical studies attempt to prevent renal injury in response to a specific insult, whereas, in clinical practice, AKI is usually established at the time therapy is being considered.…”
Section: Challenges Of Preclinical Studiesmentioning
confidence: 99%
“…16,17 It is becoming increasingly apparent that genetic heterogeneity within patient cohorts adds another element of complexity that may affect the response to promising therapies, and research initiatives in this area on relevant patient populations will hopefully inform the design of better preclinical models. 18-21 In contrast, preclinical studies are typically performed on pure disease processes with minimal consideration given to the genetic background of the model or cell line chosen. 22 The context of treatment must also be considered—many preclinical studies attempt to prevent renal injury in response to a specific insult, whereas, in clinical practice, AKI is usually established at the time therapy is being considered.…”
Section: Challenges Of Preclinical Studiesmentioning
confidence: 99%